David Sekula

1.4k total citations
25 papers, 1.1k citations indexed

About

David Sekula is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, David Sekula has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Oncology and 4 papers in Immunology. Recurrent topics in David Sekula's work include Ubiquitin and proteasome pathways (13 papers), Cancer-related Molecular Pathways (13 papers) and Retinoids in leukemia and cellular processes (12 papers). David Sekula is often cited by papers focused on Ubiquitin and proteasome pathways (13 papers), Cancer-related Molecular Pathways (13 papers) and Retinoids in leukemia and cellular processes (12 papers). David Sekula collaborates with scholars based in United States, United Kingdom and Germany. David Sekula's co-authors include Ethan Dmitrovsky, Sarah J. Freemantle, John Langenfeld, Michael J. Spinella, Jay Boyle, Hiroaki Kiyokawa, Konstantin H. Dragnev, Qing Feng, Sutisak Kitareewan and Fulvio Lonardo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and JNCI Journal of the National Cancer Institute.

In The Last Decade

David Sekula

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Sekula United States 18 850 440 213 163 127 25 1.1k
Gabriela Paroni Italy 20 1.1k 1.3× 277 0.6× 159 0.7× 203 1.2× 164 1.3× 34 1.3k
Xiao-Feng Le United States 21 910 1.1× 462 1.1× 111 0.5× 274 1.7× 105 0.8× 23 1.3k
Mirjam T. Epping Netherlands 15 1.3k 1.5× 453 1.0× 383 1.8× 168 1.0× 219 1.7× 16 1.7k
Ramon Chua United States 17 975 1.1× 357 0.8× 652 3.1× 104 0.6× 152 1.2× 20 1.4k
Charles R. Holst United States 12 840 1.0× 423 1.0× 188 0.9× 235 1.4× 173 1.4× 14 1.4k
M. J. Birrer United States 14 947 1.1× 537 1.2× 244 1.1× 337 2.1× 191 1.5× 24 1.5k
Nonggao He United States 13 723 0.9× 306 0.7× 111 0.5× 99 0.6× 116 0.9× 19 986
Alex R. Shoemaker United States 17 712 0.8× 451 1.0× 120 0.6× 212 1.3× 187 1.5× 20 1.2k
Krasil'nikov Ma Russia 16 851 1.0× 419 1.0× 160 0.8× 288 1.8× 151 1.2× 60 1.2k

Countries citing papers authored by David Sekula

Since Specialization
Citations

This map shows the geographic impact of David Sekula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sekula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sekula more than expected).

Fields of papers citing papers by David Sekula

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sekula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sekula. The network helps show where David Sekula may publish in the future.

Co-authorship network of co-authors of David Sekula

This figure shows the co-authorship network connecting the top 25 collaborators of David Sekula. A scholar is included among the top collaborators of David Sekula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sekula. David Sekula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Danilov, Alexey V., Shanhu Hu, Bernardo Orr, et al.. (2016). Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. Molecular Cancer Therapeutics. 15(11). 2758–2766. 36 indexed citations
2.
Yim, Christina Y., David Sekula, Xi Liu, et al.. (2016). G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Research. 76(5). 1204–1213. 43 indexed citations
3.
Hu, Shanhu, Yun Lu, Bernardo Orr, et al.. (2015). Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown. Molecular Cancer Therapeutics. 14(11). 2576–2585. 18 indexed citations
4.
Sekula, David, Yun Lu, Andrew J. Giustini, et al.. (2015). Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer. 15(1). 886–886. 15 indexed citations
5.
Kawakami, Masanori, Lisa Maria Mustachio, Xi Liu, et al.. (2015). Abstract 942: Novel CDK2/9 inhibitor has antineoplastic activity in lung cancer by inducing anaphase catastrophe. Cancer Research. 75(15_Supplement). 942–942. 1 indexed citations
6.
Ma, Tian, Aihua Li, Yun Lu, et al.. (2014). Mice lacking G0S2 are lean and cold-tolerant. Cancer Biology & Therapy. 15(5). 643–650. 31 indexed citations
7.
Galimberti, Fabrizio, David Sekula, Bin Li, et al.. (2014). All-trans-retinoic acid antagonizes the hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15(4). 463–472. 10 indexed citations
8.
Ma, Tian, David Sekula, Dennis Liang Fei, et al.. (2013). Repression of exogenous gene expression by the retinoic acid target gene G0S2. International Journal of Oncology. 42(5). 1743–1753. 2 indexed citations
9.
Guo, Yongli, Alexandra G. Lopez‐Aguiar, Yun Lu, et al.. (2012). Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target. Molecular Cancer Therapeutics. 11(9). 1968–1977. 36 indexed citations
10.
Galimberti, Fabrizio, Tian Ma, David Sekula, et al.. (2012). Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41(5). 1751–1761. 16 indexed citations
11.
Galimberti, Fabrizio, Tian Ma, David Sekula, et al.. (2011). Abstract 1615: Gene expression profile predicts response to smoothened inhibitors in epithelial cancers. Cancer Research. 71(8_Supplement). 1615–1615. 1 indexed citations
12.
Guo, Yongli, Bruce A. Stanton, Jennifer M. Bomberger, et al.. (2010). Blockade of the Ubiquitin Protease UBP43 Destabilizes Transcription Factor PML/RARα and Inhibits the Growth of Acute Promyelocytic Leukemia. Cancer Research. 70(23). 9875–9885. 52 indexed citations
13.
Feng, Qing, David Sekula, Yongli Guo, et al.. (2008). UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. 7(12). 3780–3788. 73 indexed citations
14.
Feng, Qing, David Sekula, Rolf Müller, Sarah J. Freemantle, & Ethan Dmitrovsky. (2007). Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene. 26(35). 5098–5106. 28 indexed citations
15.
Freemantle, Sarah J., Xi Liu, Qing Feng, et al.. (2007). Cyclin degradation for cancer therapy and chemoprevention. Journal of Cellular Biochemistry. 102(4). 869–877. 36 indexed citations
16.
Feng, Qing, David Sekula, Sarah J. Freemantle, & Ethan Dmitrovsky. (2006). Uncovering residues that regulate cyclin D1 proteasomal degradation. The FASEB Journal. 20(5). 1 indexed citations
17.
18.
Boyle, Jay O., John Langenfeld, Fulvio Lonardo, et al.. (1999). Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells. JNCI Journal of the National Cancer Institute. 91(4). 373–379. 84 indexed citations
19.
Spinella, Michael J., et al.. (1999). Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation. Journal of Biological Chemistry. 274(31). 22013–22018. 142 indexed citations
20.
Spinella, Michael J., et al.. (1998). Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene. 16(26). 3471–3480. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriela Paroni Breakdown of academic impact, for papers by Xiao-Feng Le Breakdown of academic impact, for papers by Mirjam T. Epping Breakdown of academic impact, for papers by Ramon Chua Breakdown of academic impact, for papers by Charles R. Holst Breakdown of academic impact, for papers by M. J. Birrer Breakdown of academic impact, for papers by Nonggao He Breakdown of academic impact, for papers by Alex R. Shoemaker Breakdown of academic impact, for papers by Krasil'nikov Ma
Rankless by CCL
2026